Gain Therapeutics, Inc.
Gain Therapeutics, Inc. (GANX) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
ganx · stock forecast · 8 analysts (3M) · FMP · updated Jun 9, 2026
Analyst Rating & Consensus
Based on 8 Wall Street analysts in the past 3 months
Buy
8 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$10.00
Consensus
$10.00
+491.7% upside
Low
$10.00
Median: $10 · Last Close: $1.69
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Short-Term Price Prediction
BearAlgorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-10 | $1.68 | ↓ 0.73% |
1-day model range: $1.66–$1.7. Peak: $1.7 (-0.73%).
Long-Term Stock Price Prediction
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
BEARISH
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · GANX · Jun 9, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2025-12-19 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-10-15 | BTIG | Maintains | Buy→Buy |
| 2025-10-13 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-10-07 | Maxim Group | Maintains | Buy→Buy |
| 2025-09-08 | BTIG | Maintains | Buy→Buy |
| 2025-08-13 | Roth Capital | Maintains | Buy→Buy |
| 2025-07-03 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-05-19 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-03-28 | Chardan Capital | Maintains | Buy→Buy |
| 2025-03-17 | HC Wainwright & Co. | Maintains | Buy→Buy |
Wall Street analysts have recently issued updated ratings on Gain Therapeutics, Inc. (GANX) stock. Of the recent 39 rating actions, 0 were upgrades and 1 were downgrades. 8 analysts currently cover GANX.
Analyst Recommendation Trends
GANX analyst recommendation trends show stable buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 1 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$0M
↓ 100.0% YoY
Revenue Next Year
$0M
↑ 350.0% YoY
EPS This Year
$-0.56
EPS Next Year
$-0.74
↑ 33.6% YoY
EPS ForecastReported vs Estimated
Analysts forecast GANX EPS of $-0.56 for the current fiscal year, based on estimates from 4 analysts. The GANX revenue forecast is $0M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The GANX stock forecast is supported by two independent data sources: analyst consensus ratings from 8 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus GANX price target is $10.00 (+491.7% upside), with an analyst consensus of Buy.
The GANX short-term stock prediction for tomorrow is $1.68 (-0.73%).
Gain Therapeutics, Inc. trades on NASDAQ under the ticker GANX. The GANX stock outlook for 2027 is broadly positive, supported by a Buy consensus among 88% of covering analysts.
Frequently asked questions
GANX forecast · 8 questionsAccording to 8 Wall Street analysts, the average 12-month GANX price target is $10.00, with a high forecast of $10.00 and a low of $10.00. The median price target is shown in the chart above when available. This implies +491.7% potential upside from the current price of $1.69.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.